Back to top
more

Viking Therapeutics (VKTX)

(Delayed Data from NSDQ)

$65.36 USD

65.36
2,285,449

+2.61 (4.16%)

Updated May 28, 2024 04:00 PM ET

After-Market: $65.34 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VKTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Viking Therapeutics, Inc. [VKTX]

Reports for Purchase

Showing records 181 - 200 ( 211 total )

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 181

09/12/2017

Company Report

Pages: 8

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 182

08/14/2017

Company Report

Pages: 11

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 183

08/10/2017

Company Report

Pages: 5

VX5211 Hip Fracture Results Expected in 4Q17, Reiterate Buy Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 10.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 184

07/17/2017

Company Report

Pages: 12

Hip Fracture Phase 2 Study Results Expected in 4Q17; Raising PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 25.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 185

06/19/2017

Company Report

Pages: 7

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 186

06/07/2017

Company Report

Pages: 6

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 187

05/12/2017

Company Report

Pages: 11

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 188

04/27/2017

Daily Note

Pages: 3

Discontinuation of Research Coverage

Provider: Feltl & Company

Price: 10.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 189

03/27/2017

Company Report

Pages: 6

VX5211 Phase 2 Results in Hip Fracture Expected Mid-2017; New PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 25.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 190

03/27/2017

Industry Report

Pages: 47

Agenda for Our First Annual NASH Investor Conference on April 3 in NY

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 191

03/24/2017

Company Report

Pages: 11

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 192

03/22/2017

Company Report

Pages: 8

Q4 loss better than expected, pipeline largely on track - reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 193

02/15/2017

Company Report

Pages: 7

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 194

02/14/2017

Company Report

Pages: 8

Viking gets positive results in GSD Ia, signs clinical development agreement

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 195

11/15/2016

Company Report

Pages: 10

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 196

11/11/2016

Company Report

Pages: 8

Q3 cash burn better than our model, Orphan drug status soon for X-ALD?

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 197

10/03/2016

Industry Report

Pages: 14

Introducing Our NASH Splash Report: Themes From Our Recent KOL Panel

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 50.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 198

09/27/2016

Company Report

Pages: 8

Price: 24.95

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 199

09/15/2016

Company Report

Pages: 5

We Recently Met With Management and Reiterate Our Buy Rating and $6.00 Price Target.

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 10.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 200

08/16/2016

Company Report

Pages: 10

Price: 24.95